PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Completed · Phase 1
Conditions studied: Acute Myeloid Leukemia (AML)
In brief
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining PKC412 with chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when given either after or together with daunorubicin and cytarabine in treating patients with newly diagnosed acute myeloid leukemia.
Key facts
- Study ID
- NCT00093600
- Run by
- Novartis Pharmaceuticals
- People needed
- 69
- Starts
- 2004-02-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2020-12-19
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States
- Dana Faber Cancer Institute — Boston, Massachusetts, United States
- Wayne State University/Karmanos Cancer Institute — Detroit, Michigan, United States
- MD Anderson Cancer Center/University of Texas — Houston, Texas, United States
- Novartis Investigative Site — Dresden, Germany
- Novartis Investigative Site — Mainz, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.